Is Seres Therapeutics, Inc. overvalued or undervalued?

As of 13 August 2024, the valuation grade for Seres Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently assessed as overvalued given its lack of profitability, as evidenced by a P/E ratio that is not applicable due to losses, a Price to Book Value of 1.42, and an alarming ROCE of -11917.50%.
In comparison to its peers, such as uniQure NV with a P/E of -3.6045 and Nuvation Bio, Inc. with a P/E of -3.2131, Seres Therapeutics does not demonstrate a competitive valuation. The company's recent stock performance has been poor, with a year-to-date return of -55.35%, significantly underperforming the S&P 500's 2.44% return in the same period. Overall, the combination of negative financial metrics and poor relative performance suggests that Seres Therapeutics, Inc. is overvalued at its current price of 7.42.